Skip to content

An Anti-redness Product 4-week use and 2-week relapse efficacy study

4-week consecutive use of serum and 2-week recovery for anti-redenss efficacy study (Protocol ID: C24005014)

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400088665
Enrollment
Unknown
Registered
2024-08-23
Start date
2024-04-07
Completion date
Unknown
Last updated
2024-08-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Skin redness and quality

Interventions

1:Serum 4 weeks application and 2 weeks relapse

Sponsors

Shanghai China-norm Quality Technical Service Co., Ltd.
Lead Sponsor

Eligibility

Sex/Gender
All
Age
20 Years to 40 Years

Inclusion criteria

Inclusion criteria: 1. Chinese women, 20-40 years old. 2. All skin types (including oily, dry, normal and combination skin). 3. Self-claimed sensitive skin type. 4. Presenting with following certain terms assessed by Dermatologist: Skin redness (grade=4). 5. Lactic acid sting test (positive) (score=3) evaluated by trained technician. 6. Presenting with lack of dryness, radiance, plumpness, smoothness on the face, evaluated by dermatologist. 7. Did not participate any clinical test or cosmetic product test on skin within 3 months. 8. No disagreement of dermatologist because of other reasons that exclude the participation of the volunteer. 9. In general, good health at the time of the study. 10. Willing and able to participate as evidenced by signing of informed consent and Photo release form. 11. Must be willing to comply with all study protocol requirements (pay attention to: only use the skin care products provided during the study, not take topical or oral treatment like retinol, hormone, anti-oxidant health-care products or anti-redness products which may affect the efficacy of test products).

Exclusion criteria

Exclusion criteria: 1. Pregnant or breast-feeding woman. 2. Subject deprived of rights by a court or administrative order. 3. Major subject to a guardianship order. 4. Subject residing in a health or social care establishment. 5. Subject in an emergency setting. 6. Subject with a skin disease in the test areas as well as skin allergy. 7. Subject presenting a stable or progressive serious disease (per investigator's assessment). 8. Immuno-compromised subject. 9. Subject with history of allergy to cosmetic or personal care products or ingredients. 10. Subject presenting excessive exposure to sunlight or UV radiation (investigator's assessment). 11. Subjects regularly practicing aquatic or nautical sports. 12. Subjects regularly attending a sauna. 13. Subject with cardiovascular or circulatory history. 14. Subject with a history of skin cancer or malignant melanoma. 15. Intake of antihistamines, antibiotics, corticosteroids, non-steroidal anti-inflammatories, or immune suppressants in the last 6 months before study.

Design outcomes

Primary

MeasureTime frame
Clinical Assessment by Dermatologist;

Secondary

MeasureTime frame
Skin thickness and density by Ultrasound UC22 (Courage + Khazaka);Skin Texture Analysis by VisioScan VC20;Skin microcirculation by Tivi 700 Tissue Viability Imager;Lactic Acid Test;Subjects Self-assessment Questionnaire;

Countries

CHINA

Contacts

Public ContactPING XU

Shanghai China-norm Quality Technical Service Co., Ltd.

applexp_xp@163.com+86 138 1672 7971

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026